CALGARY, May 4 /PRNewswire-FirstCall/ - Stem Cell Therapeutics Corp. ("SCT") announced today that it will be holding its Annual General Meeting (AGM) on Tuesday May 09, 2006 at 2:30pm MT. The AGM will be held in the Northcote Room at the Bow Valley Square Conference Center, 3rd floor Bow Valley Square, 205-5th Ave SW, Calgary, AB.
Several critical milestones that will be highlighted by Dr. Joseph Tucker, President and CEO, following the AGM are:
- Positive results from the Phase I clinical trial in support of NTx(TM)-265 which demonstrated that no drug related adverse events were encountered and that both drugs under study were detected in the cerebrospinal fluid following intramuscular administration. - The agreement to support a Phase IIa safety study examining the effects of NTx(TM)-265 in stroke patients. The Phase IIa safety study has been reviewed and approved by both the United States Food and Drug Administration (FDA) and by the institutional review board (IRB) of the University of California, Irvine (UCI). The study will be conducted by Dr. Steven Cramer, a leading stroke specialist at UCI.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient's own stem cells to proliferate in the brain. SCT's core technology, which includes its lead therapeutic product NTx(TM)-265, has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals. SCT plans to develop this fundamental technology further for specific disease treatments such as stroke and potentially Huntington's disease, Alzheimer's disease and other neurodegenerative conditions.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Stem Cell Therapeutics Corp.CONTACT: For further information on Stem Cell Therapeutics Corp., visitwww.stemcellthera.com or contact : Dr. Joseph Tucker, Chief ExecutiveOfficer, Stem Cell Therapeutics Corp., Phone : (403) 245-5495,info@stemcellthera.com